Pharmacology Research and Perspectives, 2021 Several therapeutic options are currently available to treat excessive daytime sleepiness (EDS) in patients suffering from narcolepsy or obstructive sleep apnea.
Stéphane Krief +2 more
exaly +2 more sources
Nature and Science of Sleep, 2021 Vivien C Abad Department of Psychiatry & Behavioral Sciences, Division of Sleep Medicine, Stanford University, Redwood City, CA 94063, USACorrespondence: Vivien C AbadDepartment of Psychiatry & Behavioral Sciences Division of Sleep Medicine ...
Vivien C Abad
exaly +2 more sources
Comparative efficacy, safety and benefit/risk of alerting agents for excessive daytime sleepiness in patients with obstructive sleep apnoea: a network meta-analysisResearch in context [PDF]
EClinicalMedicineSummary: Background: Obstructive sleep apnoea (OSA) is a common chronic respiratory disease associated with a high burden of disabilities related to sleepiness and reduced quality of life.
Jean-Louis Pépin +11 more
doaj +2 more sources
Activated wake systems in narcolepsy type 1 [PDF]
Annals of Neurology, Volume 94, Issue 4, Page 762-771, October 2023., 2023 ObjectiveNarcolepsy type 1 (NT1) is assumed to be caused solely by a lack of hypocretin (orexin) neurotransmission. Recently, however, we found an 88% reduction in corticotropin-releasing hormone (CRH)-positive neurons in the paraventricular nucleus (PVN)
Anink, J. +11 more
core +3 more sources
Effect of sleep apnoea interventions on multiple health outcomes: an umbrella review of meta-analyses of randomised controlled trialsResearch in context [PDF]
EClinicalMedicineSummary: Background: Obstructive sleep apnoea (OSA) is a prevalent chronic condition that is associated with cardiometabolic and neurocognitive complications.
Camille Figard +7 more
doaj +2 more sources
Comorbidity of obstructive sleep apnea and narcolepsy: A challenging diagnosis and complex management [PDF]
Sleep Medicine: XIntroduction: Narcolepsy and obstructive sleep apnea syndrome (OSA) are relevant causes of excessive daytime sleepiness (EDS); although different for etiopathogenesis and symptoms, differential diagnosis is sometimes difficult, and guidelines are lacking
Silvia Miano +2 more
doaj +2 more sources
Solriamfetol for Excessive Sleepiness in Obstructive Sleep Apnea (TONES 3). A Randomized Controlled Trial [PDF]
American Journal of Respiratory and Critical Care Medicine, 2019 Rationale: Primary treatment of obstructive sleep apnea can be accompanied by a persistence of excessive sleepiness despite adherence. Furthermore, effectiveness of sleep apnea treatment is limited by poor adherence. Currently available pharmacologic options for the treatment of sleepiness in this population are limited.
Russell Rosenberg +2 more
exaly +6 more sources
A Review of Current and Future Pharmacologic Treatments for Narcolepsy [PDF]
European PsychiatryIntroduction Narcolepsy is a rare but disabling neurological disorder involving disruption of the sleep-wake cycle that is often under- or misdiagnosed (Barateau L, et al. J Sleep Res. 2022;31(4):e13631).
P. Chue +4 more
doaj +2 more sources
Depressive disorders: systematic review of approved psychiatric medications (2009-April 2025) and pipeline phase 3 medications. [PDF]
BMC PsychiatryBackgroundDepressive disorders remain a significant public health concern, with substantial personal, social, and economic impacts worldwide. The purpose of this systematic review is to examine the psychiatric medications approved by the FDA from 2009 ...
IsHak WW +15 more
europepmc +3 more sources
481 Solriamfetol Titration & AdministRaTion (START): Characteristics of patients with narcolepsy and solriamfetol prescriber rationale [PDF]
Sleep, 2021 Abstract Introduction Pharmacotherapy for excessive daytime sleepiness (EDS) associated with narcolepsy is diverse, with factors such as efficacy, side effects, and tolerance influencing treatment decisions.
Michael Thorpy +6 more
openaire +2 more sources